Literature DB >> 16371545

Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer.

Koichiro Yamakado1, Atsuhiro Nakatsuka, Haruyuki Takaki, Yasuhiro Mori, Hitoshi Tonouchi, Masato Kusunoki, Hideya Kida, Kan Takeda.   

Abstract

This prospective study was conducted to evaluate the efficacy of hepatic arterial infusion chemotherapy (HAIC) with use of an implanted port followed by radiofrequency (RF) ablation for the treatment of liver metastasis of gastric cancer. Seven patients without extrahepatic metastasis were enrolled. The maximum tumor size was less than 3 cm in one patient and 3.2-6.0 cm in the other six patients (mean, 4.4 cm +/- 1.5). Two patients had single lesions and the other five patients had two to six lesions each. The maximum tumor size was reduced to 3 cm or less (mean, 2.4 cm +/- 0.4; P < .03) after HAIC in all patients. The total number of tumors was reduced from 25 to 16. RF ablation was performed for all residual liver tumors, resulting in complete tumor necrosis. All but one patient are still living without intrahepatic recurrence, with a median survival time of 16.5 months.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371545     DOI: 10.1097/01.RVI.0000188738.84911.3B

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  16 in total

Review 1.  Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines.

Authors:  Yasuhiro Kodera; Kazumasa Fujitani; Norimasa Fukushima; Seiji Ito; Kei Muro; Norifumi Ohashi; Takaki Yoshikawa; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2014-04       Impact factor: 7.370

Review 2.  Strategies for treating liver metastasis from gastric cancer.

Authors:  Yoshihiro Kakeji; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

3.  Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer.

Authors:  Si-Eun Hwang; Doo-Hyun Yang; Chan-Young Kim
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

4.  Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer.

Authors:  Mohammad H Rashid; Mersiha Hadziahmetovic; Uzair B Chaudhary
Journal:  Gastrointest Cancer Res       Date:  2012-09

5.  Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation.

Authors:  Ali Guner; Taeil Son; In Cho; In Gyu Kwon; Ji Yeong An; Hyoung-Il Kim; Jae-Ho Cheong; Sung Hoon Noh; Woo Jin Hyung
Journal:  Gastric Cancer       Date:  2015-08-01       Impact factor: 7.370

Review 6.  Clinical modalities for management of gastric cancer hepatic metastasis.

Authors:  Feng Tao; Jieqing Lv; Wei Wang; Ketao Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

7.  Radiofrequency ablation for treating liver metastases from a non-colorectal origin.

Authors:  Bo La Yun; Jeong Min Lee; Ji Hyun Baek; Se Hyung Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

Review 8.  Surgical treatment of liver metastases of gastric cancer: state of the art.

Authors:  Fabrizio Romano; Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri
Journal:  World J Surg Oncol       Date:  2012-08-03       Impact factor: 2.754

Review 9.  [Combined therapies including interventional radiology].

Authors:  S Clasen; P L Pereira
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

10.  Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma.

Authors:  Ji Yeong An; Je Yeon Kim; Min Gew Choi; Jae Hyung Noh; Dongil Choi; Tae Sung Sohn; Sung Kim
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.